Semaglutide Cuts Heavy Drinking in Landmark Lancet Trial

Why This Trial Matters

Despite decades of research into alcohol use disorder — a condition affecting an estimated 29.5 million Americans — only three medications have ever been approved by the FDA for its treatment: disulfiram (Antabuse), acamprosate, and naltrexone. All three have limited efficacy, and most people with AUD never receive any pharmacological treatment at all.

GLP-1 receptor agonists like semaglutide, originally developed for type 2 diabetes and later approved for obesity, have shown unexpected effects on reward pathways in the brain. Patients taking these drugs for weight loss began reporting that alcohol had "lost its pull" — an observation that caught the attention of addiction researchers worldwide.

The trial published in The Lancet on May 2, 2026, is among the first rigorous, randomized, double-blind, placebo-controlled studies to test whether semaglutide can actually reduce drinking in people actively seeking treatment for AUD. It was led by Dr. Anders Fink-Jensen at Copenhagen University Hospital and included scientists from the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) at the NIH.

The Trial Design

This was a single-center study. All participants were adults with both obesity (BMI of 30 or higher) and alcohol use disorder. Critically, all participants — both semaglutide and placebo groups — were also offered standard cognitive behavioral therapy sessions for AUD. This means the trial tested whether semaglutide provides additional benefit beyond evidence-based behavioral treatment.

What the Data Shows

Both groups saw reductions in heavy drinking days over the 26-week trial period — which is expected, given that everyone received CBT and was actively seeking treatment. But the reductions were significantly larger in the semaglutide group across every measured outcome.

The semaglutide group also showed greater improvements in body weight, waist circumference, BMI, and average blood sugar — benefits consistent with the drug's established metabolic effects. These dual outcomes are significant: a single medication addressing both obesity and alcohol use disorder simultaneously.

Safety and Side Effects

The side effect profile mirrored what's already well-documented for semaglutide in the diabetes and obesity context. The most common adverse events were transient, mild-to-moderate gastrointestinal symptoms: nausea, constipation, loss of appetite, diarrhea, reflux, and abdominal pain. These were more common in the semaglutide group than placebo, as expected.

Four serious adverse events were reported across the entire trial — one in the semaglutide group and three in the placebo group. All had resolved by the five-week post-trial follow-up period. No new safety signals emerged.

What the Researchers Say

"We're beginning to see some of that potential for GLP-1s to treat drug addiction turn into reality. Questions remain but this is nonetheless very encouraging." — Dr. Nora Volkow, Director, National Institute on Drug Abuse (NIDA)

"These findings are consistent with previous studies showing that GLP-1s might be an effective treatment for AUD." — Dr. George Koob, Director, National Institute on Alcohol Abuse and Alcoholism (NIAAA)

The researchers note an important limitation: the trial enrolled only participants with obesity (BMI ≥ 30) in addition to AUD. Whether semaglutide produces the same anti-craving effects in people with AUD who are not obese remains an open question that further clinical trials will need to answer.

The Bigger Picture

This trial doesn't exist in isolation. It arrives amid a surge of research linking GLP-1 medications to reduced substance use across multiple addictive substances — not just alcohol. A March 2026 study from Washington University, published in The BMJ, analyzed over 600,000 U.S. veterans and found GLP-1 use associated with reduced risk of developing substance use disorders across alcohol, cannabis, cocaine, nicotine, and opioids simultaneously.

The proposed mechanism centers on GLP-1 receptors in the brain's reward circuitry — particularly the ventral tegmental area (VTA) and nucleus accumbens. These drugs appear to modulate dopamine signaling in ways that dampen the "incentive salience" of addictive substances: they don't make alcohol taste bad or create aversion, they simply reduce the craving drive. Researchers describe it as "quieting drug noise" — the same way these medications quiet "food noise" in people taking them for obesity.

Phase 3 clinical trials evaluating semaglutide specifically for AUD are now underway, and the NIH's STAR trial (Semaglutide Therapy for Alcohol Reduction) is actively recruiting participants at NIDA's facility in Baltimore.